CompletedNCT04832724
RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)
PHASE2 · 60 planned enrolment
- Countries listed
- 1
- Registry update
- September 5, 2024
immortal.lifeTrial registrations containing the exact intervention label RGX-314.
No aliases or equivalent products have been inferred.
This is a registry availability fact, not a safety result, comparison, or conclusion.
Understand the safety boundary →PHASE2 · 60 planned enrolment
PHASE2 · 865 planned enrolment
PHASE1 · PHASE2 · 42 planned enrolment